12/4
07:18 am
traw
Traws Pharma (NASDAQ:TRAW) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $8.00 price target on the stock.
Medium
Report
Traws Pharma (NASDAQ:TRAW) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $8.00 price target on the stock.
12/3
07:02 am
traw
Traws Pharma (NASDAQ:TRAW) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Medium
Report
Traws Pharma (NASDAQ:TRAW) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
12/2
03:46 pm
traw
Traws Pharma (NASDAQ:TRAW) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Traws Pharma (NASDAQ:TRAW) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
07:40 am
traw
Traws Pharma GAAP EPS of -$0.34 [Seeking Alpha]
High
Report
Traws Pharma GAAP EPS of -$0.34 [Seeking Alpha]
11/13
07:00 am
traw
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
High
Report
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
10/30
12:31 pm
traw
Traws Pharma (NASDAQ:TRAW) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Traws Pharma (NASDAQ:TRAW) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/30
12:00 pm
traw
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
Medium
Report
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
10/22
06:40 pm
traw
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
High
Report
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
10/14
07:31 am
traw
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 [Yahoo! Finance]
Medium
Report
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 [Yahoo! Finance]
10/14
07:00 am
traw
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Neutral
Report
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
10/6
07:23 am
traw
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives [Yahoo! Finance]
Low
Report
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives [Yahoo! Finance]
10/6
07:00 am
traw
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
Low
Report
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
9/25
07:56 am
traw
Annovis Bio appoints CFO [Seeking Alpha]
Low
Report
Annovis Bio appoints CFO [Seeking Alpha]
9/25
07:44 am
traw
Annovis Appoints Mark Guerin as Chief Financial Officer [Yahoo! Finance]
Low
Report
Annovis Appoints Mark Guerin as Chief Financial Officer [Yahoo! Finance]